Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
Want to see TEM full AI Analyst Report?
TEM Stock Chart & Stats
$55.87
-$0.17(-0.45%)
At close: 4:00 PM EST
$55.87
-$0.17(-0.45%)
Day’s Range― - ―
52-Week Range$41.73 - $104.32
Previous CloseN/A
Volume1.41M
Average Volume (3M)7.36M
Market Cap
$9.13B
Enterprise Value$9.31B
Total Cash (Recent Filing)$639.07M
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)―
Beta3.07
Next Earnings
Aug 06, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding174,520,980
10 Day Avg. Volume7,795,285
30 Day Avg. Volume7,364,717
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.94
Price to Sales (P/S)8.09
P/FCF Ratio-43.03
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue6.83
Enterprise Value/Gross Profit9.81
Enterprise Value/Ebitda-68.67
Forecast
1Y Price Target
$65.93Price Target Upside18.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$1.59B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & ScaleSustained high revenue growth and $1.36B TTM scale indicate durable market demand across diagnostics and data services. Scale supports multi-year commercial investments, spreads fixed costs, and enhances bargaining power with payers and pharma partners, improving long-term revenue visibility.
Improving Unit EconomicsMaterial gross-margin expansion to ~72% signals stronger unit economics as sequencing and analytics scale. Higher gross margins create room for operating leverage, making attainment of positive adjusted EBITDA more sustainable as revenue grows and fixed R&D/SG&A are amortized.
Proprietary Data & Pharma PartnershipsA vast, proprietary clinico‑molecular dataset plus large, multi-year pharma collaborations create a durable competitive moat. Data assets enable recurring licensing, differentiated model-building, and stickier enterprise relationships that support long-term revenue and higher-margin services.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow increases dependence on external financing. Over time this can pressure liquidity, raise financing costs, and force dilution or constrained investment in commercialization, slowing progress toward self-sustaining profitability.
Elevated LeverageSizable outstanding debt relative to equity limits financial flexibility and raises fixed servicing obligations. If operational cash generation lags, leverage can constrain M&A, capital allocation, and create refinancing risk, particularly given ongoing operating losses.
MRD Reimbursement & Scaling RiskMRD shows rapid percentage growth but remains small in absolute volume and faces reimbursement and regulatory uncertainty. Delayed or limited reimbursement would force continued subsidization during scale-up, hampering margin improvement and extending time to positive cash generation.
Tempus AI, Inc. Class A News
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $41.73 and its highest was $104.32 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $9.13B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is Aug 06, 2026 which is in 46 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on May 05, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.07.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Undervalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -0.15.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 174,520,980 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -1.054%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tempus AI, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$65.93 (18.00% Upside)
$65.93 (18.00% Upside)
Blogger Sentiment
Bullish
TEM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.42%
12-Months-Change
Fundamentals
Return on Equity
-70.24%
Trailing 12-Months
Asset Growth
38.36%
Trailing 12-Months
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
TEM Company Deck
TEM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong topline momentum and durable demand in both diagnostics and data/applications: revenue growth (~36% YoY), robust Data & Insights growth (40.5% YoY; Insights >44%), expansion of large pharma collaborations (Merck, Gilead), rising bookings/TCV and an upgraded full-year revenue guide to $1.59B–$1.60B with adjusted EBITDA targeted at ~$65M. Key risks and near-term headwinds include Q1 cash-flow timing effects, slower hereditary volumes early in the year, MRD reimbursement and scaling constraints, and some regulatory timing uncertainty. Overall the positives (strong growth, expanding high-value contracts, improving EBITDA trajectory and sizable data assets) outweigh the transitory operational and reimbursement challenges.View all TEM earnings summariesTEM Stock 12 Month Forecast
Average Price Target
$65.93
▲(18.00% Upside)
Technical Analysis
Ownership Overview
22.57% Insiders
8.86% Mutual Funds
30.20% Other Institutional Investors
22.57% Public Companies and Individual Investors